Protagonist Therapeutics PTGX Accrued revenue share
Accrued revenue share at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ReceivablesLongTermContractsOrPrograms.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's accrued revenue share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's accrued revenue share?
- Protagonist Therapeutics (PTGX) reported accrued revenue share of $53.66M in Q1 2026.
- What does accrued revenue share mean?
- This metric represents the portion of revenue earned from collaborative research, licensing agreements, or milestone achievements that has been recognized under accounting standards but for which cash payment has not yet been received. It reflects the company's contractual right to consideration for performance obligations satisfied to date in its biopharmaceutical partnerships. Monitoring this balance is essential for assessing the timing of cash inflows relative to the company's clinical development milestones.